Ribosomal protein S6 mRNA is a biomarker upregulated in multiple sclerosis, downregulated by interferon treatment, and affected by season

Parnell, Grant P.; Gatt, Prudence N.; Liddle, Christopher; Slee, Mark; Vucic, Steve; Stewart, Graeme J.; Booth, David R.; McKay, Fiona C.; Schibeci, Stephen; Krupa, Malgorzata; Powell, Joseph E.; Visscher, Peter M.; Montgomery, Grant W.; Lechner-Scott, Jeannette; Broadley, Simon

Title: Ribosomal protein S6 mRNA is a biomarker upregulated in multiple sclerosis, downregulated by interferon treatment, and affected by season
Creator: Parnell, Grant P.; Gatt, Prudence N.; Liddle, Christopher; Slee, Mark; Vucic, Steve; Stewart, Graeme J.; Booth, David R.; McKay, Fiona C.; Schibeci, Stephen; Krupa, Malgorzata; Powell, Joseph E.; Visscher, Peter M.; Montgomery, Grant W.; Lechner-Scott, Jeannette; Broadley, Simon
Relation: NHMRC
Relation: Multiple Sclerosis Journal Vol. 20, Issue 6, p. 675-685
Publisher Link: http://dx.doi.org/10.1177/1352458513507819
Publisher: Sage Publications
Resource Type: journal article
Date: 2014
Description: Background: Multiple Sclerosis (MS) is an immune-mediated disease of the central nervous system which responds to therapies targeting circulating immune cells. Objective: Our aim was to test if the T-cell activation gene expression pattern (TCAGE) we had previously described from whole blood was replicated in an independent cohort. Methods: We used RNA-seq to interrogate the whole blood transcriptomes of 72 individuals (40 healthy controls, 32 untreated MS). A cohort of 862 control individuals from the Brisbane Systems Genetics Study (BSGS) was used to assess heritability and seasonal expression. The effect of interferon beta (IFNB) therapy on expression was evaluated. Results: The MS/TCAGE association was replicated and rationalized to a single marker, ribosomal protein S6 (RPS6). Expression of RPS6 was higher in MS than controls (p<0.0004), and lower in winter than summer (p<4.6E-06). The seasonal pattern correlated with monthly UV light index (R=0.82, p<0.002), and was also identified in the BSGS cohort (p<0.0016). Variation in expression of RPS6 was not strongly heritable. RPS6 expression was reduced by IFNB therapy. Conclusions: These data support investigation of RPS6 as a potential therapeutic target and candidate biomarker for measuring clinical response to IFNB and other MS therapies, and of MS disease heterogeneity.
Subject: multiple sclerosis; biomarkers; RPS6; season; interferon beta
Identifier: http://hdl.handle.net/1959.13/1303147
Identifier: uon:20620
Identifier: ISSN:1352-4585
Language: eng
Reviewed

Hits: 7811
Visitors: 7740
Downloads: 0

		Thumbnail	File	Description	Size	Format